Myriad Genetics, Inc. (MYGN) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Myriad Genetics, Inc. is a leading molecular diagnostic testing and precision medicine company. The company operates as a single reporting segment, focusing on hereditary cancer, tumor profiling, prenatal health, and pharmacogenomics. The filing reflects a period of significant strategic transition, including senior management changes and a major restructuring of the company's debt facilities.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $205.7 | $213.3 | $614.7 | $627.0 |
| Gross Profit | $143.8 | $149.8 | $429.8 | $434.5 |
| Gross Margin | 70.0% | 70.2% | 69.9% | 69.3% |
| Operating Loss | $(23.3) | $(20.0) | $(381.5) | $(84.5) |
| Net Loss | $(27.4) | $(22.1) | $(358.0) | $(84.8) |
| Diluted EPS | $(0.29) | $(0.24) | $(3.88) | $(0.94) |
| Cash & Equivalents | $145.4 | $99.9 | Balance Sheet (Sep 30, 2025) | |
| Long-Term Debt | $119.5 | $39.6 | Balance Sheet (Sep 30, 2025) | |
| Operating Cash Flow (9M) | $(8.8) | $(15.3) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 3.6% year-over-year in Q3 and 2.0% for the nine-month period. The decline was primarily driven by a $22.1 million drop in Pharmacogenomics revenue (9M) due to UnitedHealthcare coverage changes for the GeneSight test and the absence of $20.3 million in retroactive revenue recognized in the prior year.
- Significant Impairment Charges: The company recorded a non-cash goodwill and long-lived asset impairment charge of $316.7 million for the nine months ended September 30, 2025. This included $234.7 million in goodwill impairment and $82.0 million in intangible asset impairment, triggered by a sustained decline in market capitalization and downward forecast revisions.
- Debt Restructuring: In July 2025, the company entered a new $200 million credit facility, drawing an initial $125 million term loan. This replaced the previous asset-based revolving credit facility. Consequently, long-term debt increased from $39.6 million to $119.5 million, and interest expense rose significantly.
- Management Transition: The company underwent significant leadership changes in 2025, including the appointment of Samraat S. Raha as CEO, Mark S. Verratti as COO, Brian Donnelly as Chief Commercial Officer, and Benjamin R. Wheeler as CFO.
Guidance, Outlook, and Risks
- Strategic Focus: Management is pivoting to three pillars: accelerating growth in the Cancer Care Continuum (CCC), growing Prenatal and Mental Health revenues, and maintaining financial discipline to achieve profitable growth.
- Reimbursement Risks: The filing highlights ongoing pressure from third-party payors. Specifically, UnitedHealthcare's decision to stop covering certain multi-gene panel pharmacogenetic tests is expected to continue negatively impacting revenue and profitability in future periods.
- Liquidity and Covenants: The new credit facility includes a minimum trailing twelve-month revenue covenant starting at $615.0 million in December 2025, increasing to $974.0 million by December 2029. The company is currently in compliance but faces risks if revenue targets are not met.
- Legal Proceedings: The company is involved in a qui tam lawsuit regarding alleged False Claims Act violations related to physician referrals. The government declined to intervene, but the company is defending the matter.
- Regulatory Environment: While a recent court decision vacated the FDA's final rule on Laboratory Developed Tests (LDTs), uncertainty remains regarding future federal oversight, which could impose new compliance costs.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used in the Level 3 fair value measurements for the $316.7 million impairment charge, particularly the discount rates (16-17%) and revenue forecasts for the Pharmacogenomics and Women's Health units.
- Debt Covenant Compliance: Monitor the company's ability to meet the escalating revenue covenants under the new Credit Facility, starting with the $615 million threshold in Q4 2025.
- Pharmacogenomics Recovery: Assess the trajectory of the GeneSight test revenue following the UnitedHealthcare coverage change and the effectiveness of the company's strategy to leverage state biomarker laws.
- Management Execution: Evaluate the early performance of the new senior leadership team in executing the strategic pivot toward the Cancer Care Continuum and cost discipline.
- Cash Burn Rate: Review the trend in operating cash flows, which remain negative, against the company's cash balance of $145.4 million and the availability of the remaining $75 million delayed draw term loan.